Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.56 |
| ▸ | EGFR | P00533 | 11/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16705939 | 1.00 | MKNK1 (0.56) | MKNK1EGFRABL1ABL2KMO | |
| SCHEMBL16700520 | 1.00 | MKNK1 (0.56) | MKNK1EGFRABL1ABL2KMO | |
| SCHEMBL16705908 | 0.86 | MKNK1 (0.55) | MKNK1EGFRABL1ABL2KDR | |
| SCHEMBL15534270 | 0.83 | MKNK1 (0.58) | MKNK1EGFRERBB2 | |
| SCHEMBL16707855 | 0.83 | MKNK1 (0.48) | MKNK1EGFRABL1ABL2 | |
| SCHEMBL16707859 | 0.83 | MKNK1 (0.58) | MKNK1EGFRERBB2 | |
| SCHEMBL16700824 | 0.83 | MKNK1 (0.58) | MKNK1EGFRERBB2 | |
| SCHEMBL15534878 | 0.83 | MKNK1 (0.48) | MKNK1EGFRABL1ABL2 | |
| SCHEMBL16700387 | 0.83 | MKNK1 (0.48) | MKNK1EGFRABL1ABL2 | |
| SCHEMBL16700701 | 0.83 | MKNK1 (0.57) | MKNK1EGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | claimed |
| EP-2852593-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma Aktiengesellschaft (DE) | 2015-04-01 | — | — | EP | claimed |
| WO-2013174743-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-28 | — | — | WO | claimed |
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | Bayer Pharma AG (DE) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133426-A1 | SUBSTITUTED PYRROLOPYRIMIDINES | DPYD, VEGFA, FLT1 | MKNK1 2315/4885EGFR 1218/4885ABL1 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.